Who are Prophylaxis with valganciclovir plus mycophenolate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prophylaxis-with-valganciclovir-plus-mycophenolate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Prophylaxis with valganciclovir plus mycophenolate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prophylaxis with valganciclovir plus mycophenolate (Prophylaxis with valganciclovir plus mycophenolate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antiviral and immunosuppressant. Area: Immunology / Transplantation.

phase 3 Combination antiviral and immunosuppressant CMV DNA polymerase (valganciclovir); IMPDH type II (mycophenolate) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Prophylaxis with valganciclovir plus mycophenolate (Prophylaxis with valganciclovir plus mycophenolate) — University of Bologna. This combination prophylaxis regimen suppresses cytomegalovirus (CMV) replication while simultaneously reducing T-cell mediated rejection through dual immunosuppressive and antiviral mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prophylaxis with valganciclovir plus mycophenolate TARGET	Prophylaxis with valganciclovir plus mycophenolate	University of Bologna	phase 3	Combination antiviral and immunosuppressant	CMV DNA polymerase (valganciclovir); IMPDH type II (mycophenolate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antiviral and immunosuppressant class)

University of Bologna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prophylaxis with valganciclovir plus mycophenolate — Competitive Intelligence Brief. https://druglandscape.com/ci/prophylaxis-with-valganciclovir-plus-mycophenolate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab